2. GPCR/G Protein Neuronal Signaling Autophagy Apoptosis
  3. PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
  4. Matrine

Matrine  (Synonyms: Matridin-15-one; Vegard; α-Matrine)

Cat. No.: HY-N0164 Purity: ≥98.0%
COA Handling Instructions

Molarity Calculator

Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI).

For research use only. We do not sell to patients.

Matrine Chemical Structure

Matrine Chemical Structure

CAS No. : 519-02-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 99 In-stock
Solution
10 mM * 1 mL in DMSO USD 99 In-stock
Solid
100 mg USD 90 In-stock
200 mg USD 160 In-stock
500 mg USD 320 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 15 publication(s) in Google Scholar

Matrine Related Antibodies

Top Publications Citing Use of Products

    Matrine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Aug;128:110327.  [Abstract]

    Overexpression of miR-182-5p abolishes the Matrine-induced increase in caspase3 expression and decrease in Bcl-2 expression in vivo. Tumor sections are subjected to IHC staining using an antibody specific for caspase3 and Bcl-2.

    Matrine purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780.  [Abstract]

    Matrine promotes the nuclear Foxo3a localization and inhibits the levels of cytoplasmic Foxo3a. RC‑4B/C cells are treated with increasing concentrations of matrine for 24 h. The levels of Foxo3 are determined by western blotting analysis. β‑tubulin is used as cytoplasmic marker and lamin B1 is used as nuclear marker in RC‑4B/C cells. The gray values of Foxo3a is shown in histogram in different concentrations of matrine‑treated pituitary cancer cells.

    Matrine purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780.  [Abstract]

    Matrine increases the expression of pro‑apoptotic proteins in RC‑4B/C cells. RC‑4B/C cells are treated with 0.1, 0.5 and 2.5 mg/ml of matrine for 24 h and the expression of Bim, Bax and Bcl‑2 is determined by western blotting analysis. RC‑4B/C cells treated with 0.1% DMSO are used as negative controls. β‑actin is used as internal reference gene in pituitary cancer cells.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].

    IC50 & Target

    κ Opioid Receptor/KOR

     

    μ Opioid Receptor/MOR

     

    In Vitro

    Matrine (0-1.5 mg/mL, 24-72 h) inhibits the growth of A549 and SMMC-7721 cells[1].
    Matrine (25 μg/mL, 6 h) suppresses migration of A549 cells[1].
    Matrine (0-1 mg/mL, 48 h) induces apoptosis by reducing the Bcl-2/Bax protein ratios in A549 and SMMC-7721 cells[1].
    Matrine (0-1 mg/mL, 48 h) inhibits miR-182-5p expression and induces the apoptosis of PTC cells[2].
    Matrine (10 μM, 48 h) inhibits cisplatin-induced oxidative injury and inflammation in HK2 cells by reducing ROS level and pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α[4].
    Matrine (10 μM, 48 h) reverses mitochondrial function in cisplatin-induced HK2 cells by activating the SIRT3/OPA1 pathway[4].
    Matrine (0-20 nM, 12 h) promotes HepG2 cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Matrine Related Antibodies

    Cell Viability Assay[1]

    Cell Line: A549, SMMC-7721 cells
    Concentration: 0-500 μg/mL for A549 cells, 0-1.5 mg/mL for SMMC-7721 cells
    Incubation Time: 24-72 h
    Result: Inhibited the growth of A549 and SMMC-7721 cells.

    Western Blot Analysis[1]

    Cell Line: A549, SMMC-7721 cells
    Concentration: 100-250 μg/mL for A549 cells, 0.5-1 mg/mL for SMMC-7721 cells
    Incubation Time: 24 h
    Result: Down-regulated the expression of anti-apoptotic protein (Bcl-2) and up-regulated the level of pro-apoptotic protein (bax).

    Immunofluorescence[4]

    Cell Line: HK2 cells
    Concentration: 10 μM
    Incubation Time: 48 h
    Result: Increased SIRT3 expression reduced under cisplatin stimuli.
    In Vivo

    Matrine (Intragastric administration, 40 and 80 mg/kg for 16 consecutive days, xenograft male C57BL/6mice model) inhibits tumors growth and metastasis without affecting the body weight[3].
    Matrine (Intraperitoneal injections, 5 mg/kg, daily for four continuous days) attenuates renal injury and apoptosis in cisplatin-induced AKI mice, as well as reducing inflammatory responses and activating SIRT3/OPA1 axis and rescues renal mitochondrial dysfunction[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Xenograft male C57BL/6mice model (LLC cells)[3]
    Dosage: 40 and 80 mg/kg for 16 consecutive days
    Administration: Intragastric administration
    Result: Inhibited tumors growth.
    Decreased the ratio of CD206+/F4/80+, promoted the expression of CD4+ and CD8+ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.
    Animal Model: Cisplatin-induced acute kidney injury (AKI) mice model[4]
    Dosage: 5 mg/kg daily for 4 days
    Administration: Intraperitoneal injections
    Result: Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice.
    Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.
    Molecular Weight

    248.36

    Formula

    C15H24N2O
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (201.32 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 20 mg/mL (80.53 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0264 mL 20.1321 mL 40.2641 mL
    5 mM 0.8053 mL 4.0264 mL 8.0528 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 37.5 mg/mL (150.99 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 4.0264 mL 20.1321 mL 40.2641 mL 100.6603 mL
    5 mM 0.8053 mL 4.0264 mL 8.0528 mL 20.1321 mL
    10 mM 0.4026 mL 2.0132 mL 4.0264 mL 10.0660 mL
    15 mM 0.2684 mL 1.3421 mL 2.6843 mL 6.7107 mL
    20 mM 0.2013 mL 1.0066 mL 2.0132 mL 5.0330 mL
    25 mM 0.1611 mL 0.8053 mL 1.6106 mL 4.0264 mL
    30 mM 0.1342 mL 0.6711 mL 1.3421 mL 3.3553 mL
    40 mM 0.1007 mL 0.5033 mL 1.0066 mL 2.5165 mL
    50 mM 0.0805 mL 0.4026 mL 0.8053 mL 2.0132 mL
    60 mM 0.0671 mL 0.3355 mL 0.6711 mL 1.6777 mL
    80 mM 0.0503 mL 0.2517 mL 0.5033 mL 1.2583 mL
    DMSO 100 mM 0.0403 mL 0.2013 mL 0.4026 mL 1.0066 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Matrine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Matrine519-02-8Matridin-15-one Vegard α-MatrinePINK1/ParkinOpioid ReceptorAutophagyMitophagyFerroptosisApoptosisMitochondrial AutophagyNon-small cell lung cancerhepatomaapoptosisanti-oxidative stressacute kidney injury (AKI) modelA549 cellsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Matrine
    Cat. No.:
    HY-N0164
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.